New rules went into effect during 2018 on the Hong Kong stock exchange allowing companies that did not have a product on the market or generate revenue to list on the exchange.
What are key trends in the transparency compliance landscape? And, how are life sciences manufacturers tackling growing requirements
Mainz, Germany-based BioNTech – which was recently believed to be maneuvering for an initial public offering – instead raised $325 million in a Series B financing round, one of the largest single private funding rounds for a biotechnology company in European history.
A federal grand jury recently filed criminal charges against several developers for fraud involving a Vermont biotech company.
From Isolation to Anticipation: How technology continues to improve the lives of rare disease families
Working in the rare disease space has never been more rewarding than it is today. Technology is turning what was once thought to be impossible into actual, tangible realities for physicians, patients, and families. There are many exciting advancements happening now – in real time – and even more on the horizon that demand our attention and advocacy to help bring them to light.
German drugmaker Bayer signed an alliance with Arvinas Inc. to gain access to the U.S. biotech firm’s experimental protein drugs and crop protection technology in a deal worth up to $750 million.
Four biotech companies began trading on the Nasdaq this morning.
Pfizer announced plans to buy Therachon, a rare disease biotech company based in Basel, Switzerland.
Gilead Sciences Inc. and Goldfinch Bio Inc. announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.
Alphabet’s venture capital arm GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.